Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Maytansine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Salivary Gland Neoplasms 1

Interventions

Cyclophosphamide 1841 Radiotherapy 1796 Cisplatin 1627 Carboplatin 1384 Gemcitabine 1283 Paclitaxel 1183 Bevacizumab 1164 Docetaxel 1107 pembrolizumab 1101 Oxaliplatin 1058 Capecitabine 1055 Fluorouracil 985 Dexamethasone 877 Magnetic Resonance Spectroscopy 868 Nivolumab 839 Rituximab 837 Drug Therapy 795 Surveys and Questionnaires 789 Doxorubicin 762 Etoposide 744 Blood Specimen Collection 727 Radiosurgery 722 Irinotecan 710 Cytarabine 662 fludarabine 639 Leucovorin 624 Surgical Procedures, Operative 566 Lenalidomide 558 Biopsy 528 Radiation 516

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04620187 2026-02-24

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Dana-Farber Cancer Institute

Phase 2 Recruiting

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡